Search Results
Your search for ,AnY matches 8157 pages
Showing 3151 - 3200Nivolumab Plus Ipilimumab in Two New Lung Cancer Indications
The combination of nivolumab and ipilimumab was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with non–small cell lung cancer (NSCLC) in two different regimens: On May 15, 2020, the two-drug combination was approved for first-line treatment in...
Her Grandfather’s Medical Practice Inspired Nathalie LeVasseur, MD, BSc, FRCPC, to Improve the Lives of Women With Breast Cancer
At the 2018 ASCO Annual Meeting, Nathalie LeVasseur, MD, BSc, FRCPC, received the Annual Meeting Merit Award for a project titled, “Whole-Genome Sequencing in Metastatic Breast Cancer: Lessons Learned From the BC Cancer Personalized Oncogenomics Program.” Along with her clinical work, Dr....
Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
On May 1, 2020, the combination of daratumumab and hyaluronidase-fihj was approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous (SC) dosing of daratumumab.1,2 Daratumumab and hyaluronidase-fihj is for SC use only. The...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First...
New NCCN Guidelines Offer Patients Help in Recognizing Side Effects From Immunotherapy
The National Comprehensive Cancer Network (NCCN) recently announced the publication of “NCCN Guidelines for Patients: Immunotherapy Side Effects—Immune Checkpoint Inhibitors.” These new guidelines are designed to educate patients and to help them recognize immune side effects so effective...
Event-Free Survival as a Surrogate for Overall Survival in Patients With Localized Prostate Cancer Treated With Radiotherapy
In a study reported in the Journal of Clinical Oncology, Xie et al found that event-free survival including prostate-specific antigen biochemical failure as an event is not an adequate surrogate for overall survival in men receiving radiotherapy as primary therapy for localized prostate cancer....
Geographic Patterns of Early-Onset Colorectal Cancer Diagnoses in the United States
Over the past 3 decades, colorectal cancer survival in the United States has improved significantly, but in young people—particularly men diagnosed with colorectal cancer before age 50—incidence and mortality due to colorectal cancer are on the rise. Additionally, among patients with early-stage...
FDA Approves Oral Combination of Decitabine and Cedazuridine for Adult Patients With Myelodysplastic Syndromes
On July 7, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine (Inqovi) for adult patients with myelodysplastic syndromes (MDS), including the following: Previously treated and untreated de novo and secondary MDS with the following...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...
Longer-Term Results of Pivotal Study in Advanced Cutaneous Squamous Cell Carcinoma
New, longer-term data from a pivotal phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), were presented during the ASCO20 Virtual Scientific Program and discussed during a poster discussion.1 Danny Rischin, MD, of the Peter MacCallum Cancer Centre, Victoria, Australia, presented...
Final Analysis of Phase II Trial in Recurrent Platinum-Sensitive Ovarian Cancer
In a poster presentation at the ASCO20 Virtual Scientific Program, Mansoor Raza Mirza, MD, of the the Department of Oncology, Rigshopitalet, Copenhagen University Hospital, Denmark, and colleagues reported the final analysis of the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing the...
Belantamab Mafodotin Shows Activity in Relapsed or Refractory Myeloma
Treatment of relapsed or refractory multiple myeloma yielded responses with the antibody-drug conjugate belantamab mafodotin, both as a single agent and in combination with bortezomib and dexamethasone. Two reports from the DREAMM team expanded on these findings at the ASCO20 Virtual Scientific...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Advanced Bladder Cancer Survival Improved With Maintenance Avelumab
According to an interim analysis of the phase III JAVELIN Bladder 100 trial, rates of survival among patients with advanced urothelial carcinoma who did not progress on first-line platinum-based chemotherapy were significantly prolonged by maintenance therapy with avelumab and best supportive care...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?
In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...
Adding Cyclophosphamide to Bortezomib/Dexamethasone in Patients With Multiple Myeloma and Acute Kidney Injury From Cast Nephropathy
In a French trial reported in the Journal of Clinical Oncology, Bridoux et al found adding cyclophosphamide to bortezomib/dexamethasone offered no benefit for renal recovery of patients with multiple myeloma and initial cast nephropathy not requiring dialysis. Study Details In the multicenter...
Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?
In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First is ...
Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...
Meta-analysis of Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
In a systematic review and meta-analysis of observational studies reported in JAMA Oncology, Nitecki et al found that minimally invasive radical hysterectomy was associated with increased risk of recurrence and all-cause mortality vs open surgery in women with early-stage cervical cancer. Study...
Addition of First-Line Atezolizumab to Vemurafenib and Cobimetinib in Patients With Unresectable Advanced BRAF V600–Mutant Melanoma
As reported in The Lancet by Gutzmer et al, the phase III IMspire150 trial has shown that the addition of atezolizumab to BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib improved progression-free survival in first-line treatment of patients with unresectable BRAF V600–mutant...
Mortality Risk in Patients With COVID-19 and Thoracic Malignancies: Initial Report From the TERAVOLT Registry Study
As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, initial findings from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry study have identified potential factors associated with increased risk of mortality in patients infected with COVID-19...
Leaders of the PROMISE Study Address Racial Inequities in the United States
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called PROMISE (ClinicalTrials.gov identifier NCT03689595). The objectives of the study were to identify people with premalignant precursor conditions of multiple myeloma, understand the molecular...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
An Honored Poet Explores a Lust for Life on the Boundaries of Near Death
"When the technician leaves the room, I turn my head toward the screen to interpret neoplasms, the webs of nerves, the small lit fonts in which my pathology and/or future or future end might be written. The first tumor I ever saw was a darkness on that screen, round with a long craggy finger...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...
AIDS Research Led to Appreciation of the Power of Plants and Integrative Medicine in Cancer Care for Donald I. Abrams, MD
The path that led Donald I. Abrams, MD, to a career in oncology was a circuitous one. Although his love of science began when he was a student at Cleveland Heights High School in Ohio, and continued during college at Brown University, where he received an AB in molecular biology in 1972, he was...
AACR Stands Against Racial Discrimination and Inequality
On June 4, 2020, the American Association for Cancer Research (AACR) released this statement: [AACR] is outraged and saddened about the pervasive racism and social injustices toward African Americans in our country and all people of color around the world. As a scientific organization focused on...
Pigeon English
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of tolerating cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Polio and Cancer Survivor Mickie McGraw Channels the Power of Creative Arts to Heal Broken Bodies and Minds
GUEST EDITOR Dr. Abraham is Professor of Medicine, Lerner College of Medicine, and Chair of the Hematology and Medical Oncology Department at Taussig Cancer Institute, Cleveland Clinic. In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with pioneering art ...
Pomalidomide for Treatment of Kaposi Sarcoma
On May 14, 2020, pomalidomide was granted accelerated approval to treat adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and for Kaposi sarcoma in adult patients who are HIV-negative.1,2 Pomalidomide is available only through the restricted...
You-Can-Do-Anything Philosophy Early in Life Inspired Breast Surgeon Laura S. Dominici, MD
Breast surgical oncologist Laura S. Dominici, MD, was born and reared in Litchfield, a small town in the southern portion of New Hampshire. “Our house was on a long dirt road, in a very rural area,” she shared. “There were only about 5,000 residents in the town. My mother was a teacher, and my dad...
Woman With an Ovarian Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Brigatinib for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 22, 2020, brigatinib was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion...
ASCO Survey on Early Impact of COVID-19 on Performance of Oncology Clinical Trials
In an article published in JCO Oncology Practice, David Waterhouse, MD, MPH, of Oncology Hematology Care, Cincinnati, Ohio, and colleagues presented the results of a recent ASCO survey of clinical programs on the early impact of the COVID-19 pandemic on the performance of oncology clinical...
Ruxolitinib Improves Response Rates in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Allogeneic SCT
In the phase III REACH2 trial reported in TheNew England Journal of Medicine, Robert Zeiser, MD, of the Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Germany, and colleagues found that the JAK1/2 inhibitor ruxolitinib improved response rate...
Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Previously Untreated CLL
As reported inThe Lancet by Jeff P. Sharman, MD, of Willamette Valley Cancer Institute/US Oncology, Eugene, Oregon, and colleagues, the phase III ELEVATE-TN trial has shown significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs...
Ramucirumab Plus Erlotinib in Treatment of EGFR-Mutant Metastatic NSCLC
On May 29, 2020, ramucirumab was approved for use in combination with erlotinib for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.1,2 Supporting Efficacy Data Approval was based on findings from the...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Improving Care for Women With Late-Stage Breast Cancer
The global toll of breast cancer on women is staggering. In 2018, nearly two million new breast cancer cases were diagnosed, an increase of more than 20% since 2008,1 and mortality rates have increased by 14%, bringing the annual number of deaths worldwide from the cancer to more than 611,625.2...
Olaparib for Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, 2020, olaparib was approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who experienced disease progression after treatment with...
Ripretinib in Previously Treated Advanced Gastrointestinal Stromal Tumor
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 15, 2020, the receptor tyrosine kinase inhibitor...
Responding to Racism and Health Inequality as a Cancer Care Community
Months ago, when I defined a theme for my year as ASCO President, “Equity: Every Patient. Every Day. Everywhere,” I never imagined we would experience a health-care pandemic that would disproportionally impact people of color. Nor could I know this would be the moment when yet another brutal crime ...
Expert Point of View: Taofeek Kunie Owonikoko, MD, PhD
Study discussant Taofeek Kunie Owonikoko, MD, PhD, Professor and Vice Chair of Hematology/Oncology, Winship Cancer Institute at Emory University, Atlanta, had praise for the design of KEYNOTE-604. He noted the adoption of the combination of pembrolizumab plus etoposide/platinum for the treatment of ...
Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study
As reported in The Lancet by Kuderer et al, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of severe COVID-19 in patients with cancer is associated with such factors as age, comorbidities, performance status, hematologic malignancy, and...
Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
Lipophilic Statins May Reduce Mortality in Patients With Ovarian Cancer
Lipophilic statins—a type of medication commonly prescribed to lower blood cholesterol—were associated with reduced mortality in patients with ovarian cancer, according to a study presented by Kala Visvanathan, MD, MHS, and colleagues at the American Association for Cancer Research (AACR) Virtual...
